Adjuvant trastuzumab for HER2-positive breast cancer.

By J. Spicer, M. Harries, P. Ellis. The Lancet, 2005

1,021 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. (2015, background): “Clinical benefit, toxicity, net health benefit (NHB), and cost of two regimens when compared with standard-of-care regimen used in clinical trial for adjuvant treatment of human epidermal growth factor receptor 2–positive breast cancer: (A) doxorubicin plus cyclophosphamide followed by paclitaxel pl”
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014, background): “75).(9) This trial was not designed to assess whether the cumulative risk of DFS differed between the two trastuzumabcontaining regimens.”
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, neutral): “anthracycline may also argue against trastuzumab [115]”
A Systematic Review and Meta-analysis (2011, neutral): “Administration of 12months trastuzumab with adjuvant chemotherapy significantly improves the survival outcomes and is the standard-of-care for patients with human epidermal receptor 2 positive (HER2+) operable breast cancer.([1,2]) After a median follow-up of 11years, the results of HERA study furth”